Population Health Research Institute — Biomedical Watch V2

Traitements10programmes

Essais5liés

Publications0liées

SourceDBlocale

Traitements

10

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Active ColchicineThe prevention of perioperative atrial fibrillation (AF) and myocardial injury after non-cardiac surgery (MINS) has the potential to reduce mortality, stroke, and hospital stays in patients undergoing major thoracic surgery. Data from cardiac surgery patients suggest that prevention of perioperative atrial fibrillation using an anti-inflammatory agent, such as colchicine, is feasible. The COP-AF trial will assess whether the administration of oral colchicine will reduce the incidence of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery.	Maladie coronarienne	Phase 3	Immunomodulation	United States, Austria, Belgium, Canada, Colombia, Hong Kong, Italy, Malaysia, …	À vérifier
Angiography-guided NCL PCICOMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.	Maladie coronarienne	Non applicable	À vérifier	United States, Australia, Austria, Canada, Denmark, Finland, Germany, Greece, …	À vérifier
Colchicine 0.5 MG Oral TabletDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Maladie coronarienne, Sclérose latérale amyotrophique	Phase 3	Ralentissement de la progression	United States, Australia, Belgium, Brazil, Canada, Ecuador, Germany, Netherlands, …	À vérifier
EdoxabanTo assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage.	Accident vasculaire cérébral	Phase 4	À vérifier	United States, Argentina, Austria, Belgium, Canada, China, Czechia, Egypt, …	À vérifier
Physiology-guided NCL PCICOMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.	Maladie coronarienne	Non applicable	À vérifier	United States, Australia, Austria, Canada, Denmark, Finland, Germany, Greece, …	À vérifier
Colchicine 0.5 MG Oral TabletDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Phase 2	Ralentissement de la progression	Italy	À vérifier
Active ColchicineThe prevention of perioperative atrial fibrillation (AF) and myocardial injury after non-cardiac surgery (MINS) has the potential to reduce mortality, stroke, and hospital stays in patients undergoing major thoracic surgery. Data from cardiac surgery patients suggest that prevention of perioperative atrial fibrillation using an anti-inflammatory agent, such as colchicine, is feasible. The COP-AF trial will assess whether the administration of oral colchicine will reduce the incidence of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery.	Maladie coronarienne	Phase 3	Immunomodulation	United States, Austria, Belgium, Canada, Colombia, Hong Kong, Italy, Malaysia, Pakistan, Spain, Switzerland	À vérifier
Colchicine 0.5 MG Oral TabletThe goal of this clinical trial is to evaluate whether low-dose colchicine can slow disease progression in patients with amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder affecting motor neurons. The study is designed to answer whether patients receiving colchicine show a slower decline in functional status, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), over a 30-week double-blind treatment period compared to patients receiving placebo. Additional questions include whether colchicine has an effect on respiratory function, disability progression, quality of life, and overall survival. Researchers will compare participants receiving colchicine at a dose of 0.005 mg/kg/day with those receiving placebo, both in addition to standard-of-care therapy with riluzole, to assess potential differences in disease progression. Participants will be randomly assigned in a 2:1 ratio to colchicine or placebo. They will take the assigned study medication for 30 weeks during a double-blind phase and then continue into a 36-week open-label extension phase, during which all participants will receive colchicine while remaining blinded to their initial treatment assignment. Throughout the study, participants will undergo regular clinical evaluations, including assessments of motor and respiratory function, functional disability, and quality of life, for a total follow-up period of up to 66 weeks. Blood samples will also be collected to investigate biological markers of neurodegeneration and inflammation.	Maladie coronarienne	Phase 3	Ralentissement de la progression	United States, Australia, Belgium, Brazil, Canada, Ecuador, Germany, Netherlands, Switzerland, United Kingdom	À vérifier
EdoxabanTo assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage.	Accident vasculaire cérébral	Phase 4	À vérifier	United States, Argentina, Austria, Belgium, Canada, China, Czechia, Egypt, Germany, India, Nepal, Portugal, Spain, Switzerland, United Kingdom	À vérifier
Physiology-guided NCL PCICOMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.	Maladie coronarienne	Non applicable	À vérifier	United States, Australia, Austria, Canada, Denmark, Finland, Germany, Greece, Hungary, India, Ireland, Italy, Netherlands, Norway, Poland, Serbia, South Africa, Spain, Sweden, United Kingdom	À vérifier

Essais cliniques

5

Molécule	Indication / population	Phase	NCT	Titre	Statut
Physiology-guided NCL PCI	Maladie coronarienne	Non applicable	NCT05701358	COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease	ACTIVE_NOT_RECRUITING
Edoxaban	Accident vasculaire cérébral	Phase 4	NCT03950076	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)	COMPLETED
Colchicine 0.5 MG Oral Tablet	Maladie coronarienne	Phase 3	NCT04774159	LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk	RECRUITING
Active Colchicine	Maladie coronarienne	Phase 3	NCT03310125	Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)	COMPLETED
Colchicine 0.5 MG Oral Tablet	Sclérose latérale amyotrophique	Phase 2	NCT07813858	CO-ALSII — Colchicine Effect on Amyotrophic Lateral Sclerosis Patients	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.